<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059826</url>
  </required_header>
  <id_info>
    <org_study_id>ACOSOG-Z05031</org_study_id>
    <secondary_id>CDR0000298776</secondary_id>
    <nct_id>NCT00059826</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of Interferon-Based Adjuvant Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may&#xD;
      interfere with the growth of tumor cells. Radiation therapy uses high-energy radiation from&#xD;
      x-rays and other sources to kill tumor cells. Combining chemotherapy with interferon alfa and&#xD;
      giving them with radiation therapy after surgery may kill any remaining tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of adjuvant chemoradiotherapy and&#xD;
      interferon alfa in treating patients who have resected stage I, stage II, or stage III&#xD;
      pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the disease-free and overall survival of patients with resected pancreatic&#xD;
           adenocarcinoma treated with adjuvant chemoradiotherapy comprising fluorouracil,&#xD;
           cisplatin, and interferon alfa.&#xD;
&#xD;
        -  Determine the rate and severity of acute and late toxic effects in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the local-regional disease control and distant disease control in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Chemoradiotherapy (CRT): Patients receive fluorouracil IV continuously on days 1-38;&#xD;
           cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36; and interferon alfa&#xD;
           subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, and&#xD;
           38. Patients also undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, 29-33, and&#xD;
           36-38.&#xD;
&#xD;
        -  Post-CRT chemotherapy: Beginning 4-6 weeks after the completion of CRT, patients receive&#xD;
           fluorouracil IV continuously on days 1-42. Treatment repeats every 56 days for a total&#xD;
           of two courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 2 years, every 3 months for 1 year, every 4 months&#xD;
      for 1 year, every 6 months for 1 year, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 18 months</measure>
    <time_frame>at 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>at 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>at 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional disease control</measure>
    <time_frame>at 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease control</measure>
    <time_frame>at 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Interferon-based chemoradiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: Chemoradiotherapy (CRT)&#xD;
5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs&#xD;
cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)&#xD;
IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks&#xD;
XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks&#xD;
Cycles 2 and 3: Post-CRT Chemotherapy&#xD;
Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).&#xD;
-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>interferon-alfa-2b</intervention_name>
    <description>IV</description>
    <arm_group_label>Interferon-based chemoradiation therapy</arm_group_label>
    <other_name>IFN-alpha-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>IV</description>
    <arm_group_label>Interferon-based chemoradiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>IV</description>
    <arm_group_label>Interferon-based chemoradiation therapy</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Interferon-based chemoradiation therapy</arm_group_label>
    <other_name>XRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must be &gt; 18 years of age.&#xD;
&#xD;
          2. Patient must have a documented ECOG/Zubrod performance status of 0 or 1, within 7 days&#xD;
             prior to registration.&#xD;
&#xD;
          3. Patient must have pathological stage T1-3, N0-1, M0 adenocarcinoma of the head of the&#xD;
             pancreas according to the American Joint Committee on Cancer (AJCC) staging system.&#xD;
&#xD;
               -  NOTE: The pathology report must be submitted to ACOSOG on the Pathology Report&#xD;
                  Shuttle CRF.&#xD;
&#xD;
          4. Patient must have undergone a potentially curative gross total resection by&#xD;
             pancreaticoduodenectomy (includes R0 [no residual tumor] or R1 [microscopic residual&#xD;
             tumor]) within 56 days prior to beginning treatment. NOTE: The operative report must&#xD;
             be submitted to ACOSOG on the Operative Report Shuttle CRF.&#xD;
&#xD;
          5. Patient must have stable or increasing weight in the 14 days prior to the start of&#xD;
             treatment, otherwise supplemental nutrition (e.g. feeding jejunostomy, PEG, TPN) must&#xD;
             be initiated prior to the start of treatment.6. Patient must have adequate bone&#xD;
             marrow, hepatic and renal function, within 7 days prior to registration:&#xD;
&#xD;
               -  WBC &gt; 3,000 mm^3&#xD;
&#xD;
               -  ANC &gt; 1,500 mm^3&#xD;
&#xD;
               -  hemoglobin &gt; 9.5 mg/dl&#xD;
&#xD;
               -  platelet count &gt; 100,000 mm^3&#xD;
&#xD;
               -  total bilirubin &lt; 3 mg/dl&#xD;
&#xD;
               -  AST (SGOT) &lt; 2.0 times institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT (SGPT) &lt; 2.0 times institutional ULN&#xD;
&#xD;
               -  alkaline phosphatase &lt; 2.0 times institutional ULN&#xD;
&#xD;
               -  serum creatinine &lt; 1.5 times institutional ULN&#xD;
&#xD;
        7. Patient must have a baseline diagnostic CT scan of the chest and CT scan with IV&#xD;
        contrast (or MRI) of abdomen/pelvis, within 30 days prior to registration, to exclude&#xD;
        metastatic disease.&#xD;
&#xD;
        8. If female of childbearing potential, patient must have a negative urine or serum&#xD;
        pregnancy test, within 7 days prior to registration. NOTE: Postmenopausal women must have&#xD;
        been amenorrheic for at least 12 consecutive months to be considered not of childbearing&#xD;
        potential.&#xD;
&#xD;
        9. Patient (male or female) of reproductive potential must agree to use medically&#xD;
        acceptable contraception during the study. NOTE: Medically acceptable contraceptives&#xD;
        include: (1) surgical sterilization, (2) approved hormonal contraceptives (such as birth&#xD;
        control pills, Depo-Provera, or Lupron Depot), (3) barrier methods (such as a condom or&#xD;
        diaphragm) used with a spermicide, or (4) an intrauterine device (IUD).&#xD;
&#xD;
        10. Patient, or the patient's legally acceptable representative, must sign and date an&#xD;
        informed consent PRIOR to registration and the performance of any study related procedures.&#xD;
&#xD;
        11. Patient, or the patient's legally acceptable representative, must provide written&#xD;
        authorization to allow the use and disclosure of their protected health information.&#xD;
&#xD;
        - NOTE: This may be obtained in either the study-specific informed consent or in a separate&#xD;
        authorization form and must be obtained from the patient prior to study registration.&#xD;
&#xD;
        12. If patient is a cancer survivor, all of the following criteria must be met and&#xD;
        documented in the patient's medical record:&#xD;
&#xD;
          1. Patient has undergone potentially curative therapy for all prior malignancies.&#xD;
&#xD;
          2. No evidence of prior malignancies for at least 5 years (except for successfully&#xD;
             treated cervical carcinoma in situ, lobular carcinoma in situ of the breast, or&#xD;
             nonmelanoma skin cancer).&#xD;
&#xD;
          3. No evidence of recurrence of any prior malignancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has pancreaticoduodenectomy histopathology of adenosquamous carcinoma,&#xD;
             ampullary carcinoma, carcinoid tumor, cystadenocarcinoma, cystadenoma, distal common&#xD;
             bile duct carcinoma, duodenal carcinoma, or islet cell carcinoma.&#xD;
&#xD;
          2. Patient is pregnant or lactating.&#xD;
&#xD;
          3. Patient has recurrent pancreatic cancer.&#xD;
&#xD;
          4. Patient has received prior systemic chemotherapy or radiotherapy for pancreatic&#xD;
             cancer.&#xD;
&#xD;
          5. Patient has received external beam photon (x-ray) therapy to the chest, abdomen or&#xD;
             pelvis.&#xD;
&#xD;
          6. Patient has received any biologic/ immunologic therapies.&#xD;
&#xD;
          7. Patient has received chronic immunotherapy (e.g. prednisone or methotrexate) for&#xD;
             collagen vascular disease or other chronic immunologic abnormality.&#xD;
&#xD;
          8. Patient has a preexisting psychiatric condition, especially depression, or a history&#xD;
             of severe psychiatric disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent J. Picozzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Floyd &amp; Delores Jones Cancer Institute at Virginia Mason Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center at University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview University Medical Center - University Campus</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW; American College of Surgeons Oncology Group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011 Feb;22(2):348-54. doi: 10.1093/annonc/mdq384. Epub 2010 Jul 29.</citation>
    <PMID>20670978</PMID>
  </results_reference>
  <results_reference>
    <citation>Picozzi VJ, Abrams RA, Traverso LW, et al.: ACOSOG Z05031: initial report of a multicenter, phase II trial of a novel chemoradiation protocol using cisplatin, 5-FU, and alpha- interferon as adjuvant therapy for resected pancreas cancer. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-125, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Picozzi VJ, Abrams RA, Traverso LW, et al.: ACOSOG Z05031: report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon. [Abstract] J Clin Oncol 26 (Suppl 15): A-4505, 2008.</citation>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

